Institution
Integrated DNA Technologies
Company•Coralville, Iowa, United States•
About: Integrated DNA Technologies is a company organization based out in Coralville, Iowa, United States. It is known for research contribution in the topics: Oligonucleotide & RNA. The organization has 189 authors who have published 280 publications receiving 14567 citations.
Topics: Oligonucleotide, RNA, RNA interference, Nucleic acid, Gene silencing
Papers published on a yearly basis
Papers
More filters
••
TL;DR: These results provide an alternative strategy for eliciting RNAi-mediated target cleavage using low concentrations of synthetic RNA as substrates for cellular Dicer-mediated cleavage.
Abstract: RNA interference (RNAi) is the process of sequence-specific post-transcriptional gene silencing triggered by double-stranded RNAs. In attempts to identify RNAi triggers that effectively function at lower concentrations, we found that synthetic RNA duplexes 25–30 nucleotides in length can be up to 100-fold more potent than corresponding conventional 21-mer small interfering RNAs (siRNAs). Some sites that are refractory to silencing by 21-mer siRNAs can be effectively targeted by 27-mer duplexes, with silencing lasting up to 10 d. Notably, the 27-mers do not induce interferon or activate protein kinase R (PKR). The enhanced potency of the longer duplexes is attributed to the fact that they are substrates of the Dicer endonuclease, directly linking the production of siRNAs to incorporation in the RNA-induced silencing complex. These results provide an alternative strategy for eliciting RNAi-mediated target cleavage using low concentrations of synthetic RNA as substrates for cellular Dicer-mediated cleavage.
1,028 citations
••
TL;DR: Approval is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006, and on select publications that demonstrate interesting applications of these principles.
633 citations
••
TL;DR: An unbiased bacterial screen yields a Cas9 variant that retains high on-target activity when delivered in the RNP format and is anticipated that HiFi Cas9 will have wide utility for both basic science and therapeutic genome-editing applications.
Abstract: Translation of the CRISPR-Cas9 system to human therapeutics holds high promise. However, specificity remains a concern especially when modifying stem cell populations. We show that existing rationally engineered Cas9 high-fidelity variants have reduced on-target activity when using the therapeutically relevant ribonucleoprotein (RNP) delivery method. Therefore, we devised an unbiased bacterial screen to isolate variants that retain activity in the RNP format. Introduction of a single point mutation, p.R691A, in Cas9 (high-fidelity (HiFi) Cas9) retained the high on-target activity of Cas9 while reducing off-target editing. HiFi Cas9 induces robust AAV6-mediated gene targeting at five therapeutically relevant loci (HBB, IL2RG, CCR5, HEXB, and TRAC) in human CD34+ hematopoietic stem and progenitor cells (HSPCs) as well as primary T cells. We also show that HiFi Cas9 mediates high-level correction of the sickle cell disease (SCD)-causing p.E6V mutation in HSPCs derived from patients with SCD. We anticipate that HiFi Cas9 will have wide utility for both basic science and therapeutic genome-editing applications.
512 citations
••
TL;DR: Together, these data demonstrate that there are preexisting humoral and cell-mediated adaptive immune responses to Cas9 in humans, a finding that should be taken into account as the CRISPR–Cas9 system moves toward clinical trials.
Abstract: The CRISPR–Cas9 system is a powerful tool for genome editing, which allows the precise modification of specific DNA sequences. Many efforts are underway to use the CRISPR–Cas9 system to therapeutically correct human genetic diseases1–6. The most widely used orthologs of Cas9 are derived from Staphylococcus aureus and Streptococcus pyogenes5,7. Given that these two bacterial species infect the human population at high frequencies8,9, we hypothesized that humans may harbor preexisting adaptive immune responses to the Cas9 orthologs derived from these bacterial species, SaCas9 (S. aureus) and SpCas9 (S. pyogenes). By probing human serum for the presence of anti-Cas9 antibodies using an enzyme-linked immunosorbent assay, we detected antibodies against both SaCas9 and SpCas9 in 78% and 58% of donors, respectively. We also found anti-SaCas9 T cells in 78% and anti-SpCas9 T cells in 67% of donors, which demonstrates a high prevalence of antigen-specific T cells against both orthologs. We confirmed that these T cells were Cas9-specific by demonstrating a Cas9-specific cytokine response following isolation, expansion, and antigen restimulation. Together, these data demonstrate that there are preexisting humoral and cell-mediated adaptive immune responses to Cas9 in humans, a finding that should be taken into account as the CRISPR–Cas9 system moves toward clinical trials. Cas9-specific antibodies and reactive T cells are found in the majority of healthy adult human serum samples analyzed. Such preexisting adaptive immunity should be taken into consideration as the CRISPR–Cas9 system moves toward clinical trials.
491 citations
••
TL;DR: This review will examine studies that document the utility of various chemical modifications for use in siRNAs, both in vitro and in vivo, with close attention given to reports demonstrating actual performance in animal model systems.
Abstract: Well over a hundred reports have been published describing use of synthetic small-interfering RNAs (siRNAs) in animals. The majority of these reports employed unmodified RNA duplexes. While unmodified RNA is the natural effector molecule of RNA interference, certain problems arise with experimental or therapeutic use of RNA duplexes in vivo, some of which can be improved or solved through use of chemical modifications. Judicious use of chemical modifications can improve the nuclease stability of an RNA duplex, decrease the likelihood of triggering an innate immune response, lower the incidence of off-target effects (OTEs), and improve pharmacodynamics. This review will examine studies that document the utility of various chemical modifications for use in siRNAs, both in vitro and in vivo, with close attention given to reports demonstrating actual performance in animal model systems.
476 citations
Authors
Showing all 189 results
Name | H-index | Papers | Citations |
---|---|---|---|
Kathleen L. Gould | 69 | 206 | 15016 |
Mark A. Behlke | 60 | 204 | 13396 |
Arjun Raj | 50 | 131 | 18166 |
Andrew Tsourkas | 44 | 151 | 8473 |
Brian S. Sproat | 41 | 90 | 4959 |
Roxanne Y. Walder | 33 | 54 | 4223 |
John M. Dagle | 30 | 93 | 3032 |
Eric J. Devor | 30 | 170 | 3407 |
Paul B. Samollow | 28 | 75 | 3245 |
Zhiliang Cheng | 27 | 60 | 3595 |
Joseph A. Walder | 23 | 31 | 3604 |
Christopher A. Vakulskas | 22 | 37 | 2338 |
Kim A. Lennox | 18 | 28 | 2361 |
Rolf Turk | 17 | 36 | 1336 |
Ashley M. Jacobi | 17 | 32 | 1378 |